Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection - A pilot study

被引:6
作者
Arends, S [1 ]
vanHalteren, E [1 ]
Kamp, W [1 ]
Schokker, J [1 ]
机构
[1] FIGHT LIFE,1017 ET AMSTERDAM,NETHERLANDS
来源
PHARMACY WORLD & SCIENCE | 1996年 / 18卷 / 01期
关键词
acquired immunodeficiency syndrome; adverse effects; AIDS-related complex; CD4-positive T-lymphocytes; clinical trials; human immunodeficiency virus; 9-(2-phosphonylmethoxyethyl)adenine;
D O I
10.1007/BF00449687
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The compound 9-(2-phosphonylmethoxyethyl)adenine (PMEA) is a potent inhibitor of a number of viruses in vitro, such as human immunodeficiency virus types 1 and 2, herpes simplex virus types 1 and 2, hepatitis B virus, cytomegalovirus, and Epstein-Barr virus. PMEA also proved to be effective in vivo against feline immunodeficiency virus in cats and simian immunodeficiency virus in rhesus monkeys. In an open, non-placebo-controlled trial, the safety of weekly doses of PMEA in 10 patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex was studied for a period of 11 weeks. CD4+ T-cell counts at baseline were between 10 and 450/mm(3). The drug was administered intravenously at a dose of 1000 mg. No serious side-effects were seen. On one occasion one patient showed alanine aminotransferase and aspartate aminotransferase levels 5 times higher than the upper limit of normal and another patient showed on one occasion aspartate aminotransferase levels 5 limes higher than the upper limit of normal. In another patient serum amalyse levels increased, on one occasion 1.5 times above the upper limit of normal. An improvement in general well-being was reported by all patients. For patients with a CD4+ T-cell count >100/mm(3) at baseline, the CD4+ T-cell count increased from a mean of 283/mm(3) at baseline to a mean of 448/mm(3) at the end of the study. Repeat infusions of PMEA at a dose of 1000 mg were safe and well tolerated. Our results suggest that PMEA, administrated according to this treatment schedule, may be effective in treating patients with human immunodeficiency virus infection.
引用
收藏
页码:30 / 34
页数:5
相关论文
共 35 条
[1]   MARKED INVIVO ANTIRETROVIRUS ACTIVITY OF 9-(2-PHOSPHONYLMETHOXY-ETHYL)ADENINE, A SELECTIVE ANTI-HUMAN IMMUNODEFICIENCY VIRUS AGENT [J].
BALZARINI, J ;
NAESENS, L ;
HERDEWIJN, P ;
ROSENBERG, I ;
HOLY, A ;
PAUWELS, R ;
BABA, M ;
JOHNS, DG ;
DECLERCQ, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (01) :332-336
[2]   ANTIRETROVIRUS ACTIVITY OF 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE (PMEA) INVIVO INCREASES WHEN IT IS LESS FREQUENTLY ADMINISTERED [J].
BALZARINI, J ;
NAESENS, L ;
DECLERCQ, E .
INTERNATIONAL JOURNAL OF CANCER, 1990, 46 (02) :337-340
[3]   INTRACELLULAR METABOLISM AND MECHANISM OF ANTIRETROVIRUS ACTION OF 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE, A POTENT ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS COMPOUND [J].
BALZARINI, J ;
ZHANG, H ;
HERDEWIJN, P ;
JOHNS, DG ;
DECLERCQ, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (04) :1499-1503
[4]   9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE (PMEA) EFFECTIVELY INHIBITS RETROVIRUS REPLICATION INVITRO AND SIMIAN IMMUNODEFICIENCY VIRUS-INFECTION IN RHESUS-MONKEYS [J].
BALZARINI, J ;
NAESENS, L ;
SLACHMUYLDERS, J ;
NIPHUIS, H ;
ROSENBERG, I ;
HOLY, A ;
SCHELLEKENS, H ;
DECLERCQ, E .
AIDS, 1991, 5 (01) :21-28
[5]   ACTIVITY OF ACYCLIC NUCLEOSIDE PHOSPHONATE ANALOGS AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS IN MONOCYTE MACROPHAGES AND PERIPHERAL-BLOOD LYMPHOCYTES [J].
BALZARINI, J ;
PERNO, CF ;
SCHOLS, D ;
DECLERCQ, E .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 178 (01) :329-335
[6]   ENHANCEMENT OF NATURAL-KILLER ACTIVITY AND INTERFERON INDUCTION BY DIFFERENT ACYCLIC NUCLEOSIDE PHOSPHONATES [J].
CALIO, R ;
VILLANI, N ;
BALESTRA, E ;
SESA, F ;
HOLY, A ;
BALZARINI, J ;
DECLERCQ, E ;
PERNO, CF ;
DELGOBBO, V .
ANTIVIRAL RESEARCH, 1994, 23 (01) :77-89
[7]  
CERNY J, 1991, MOL PHARMACOL, V42, P537
[8]   COMBINATION THERAPY WITH ZIDOVUDINE AND DIDANOSINE COMPARED WITH ZIDOVUDINE ALONE IN HIV-1 INFECTION [J].
COLLIER, AC ;
COOMBS, RW ;
FISCHL, MA ;
SKOLNIK, PR ;
NORTHFELT, D ;
BOUTIN, P ;
HOOPER, CJ ;
KAPLAN, LD ;
VOLBERDING, PA ;
DAVIS, LG ;
HENRARD, DR ;
WELLER, S ;
COREY, L .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) :786-793
[9]   PHOSPHONYLMETHOXYALKYL PURINE AND PYRIMIDINE-DERIVATIVES FOR TREATMENT OF OPPORTUNISTIC CYTOMEGALOVIRUS AND HERPES-SIMPLEX VIRUS-INFECTIONS IN MURINE AIDS [J].
DECASTRO, LM ;
KERN, ER ;
DECLERCQ, E ;
GHAFFAR, A ;
MAYER, EP ;
VOGT, PE ;
GANGEMI, JD .
ANTIVIRAL RESEARCH, 1991, 16 (01) :101-114
[10]   EFFICACY OF PHOSPHONYLMETHOXYALKYL DERIVATIVES OF ADENINE IN EXPERIMENTAL HERPES-SIMPLEX VIRUS AND VACCINIA VIRUS-INFECTIONS INVIVO [J].
DECLERCQ, E ;
HOLY, A ;
ROSENBERG, I .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (02) :185-191